PPARA and metabolic dysfunction-associated steatohepatitis: In some ways, combining different targets, like PPAR-γ and PPAR-α combined agonist therapy, is thought to be effective in controlling fructose-induced NASH (66) and pan-PPAR agonists are found to improve in MAFLD treatment (48, 63).